Development asset linked to ABEONA THERAPEUTICS in public FDA and regional records.
pharma · MPS IIIA · Epidermolysis Bullosa · ABEO
ABEONA THERAPEUTICS
ABEONA THERAPEUTICS INC.
ABEONA THERAPEUTICS drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Cleveland, USA HQ
2015 Founded
228 Employees
Public company Type
ABEO · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cleveland, USA
- Founded
- 2015
- Employees
- 228
- Programs
- 8
- Drugs
- 3
- Patents
- 0
ABEONA THERAPEUTICS pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ABEONA THERAPEUTICS drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
Development asset linked to ABEONA THERAPEUTICS in public FDA and regional records.